Compare CVS Health Corp (CVS) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? CVS Health Corp trades at $93.74 (market cap $122.36B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6. The key difference: CVS Health Corp pays a 2.78% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and CVS Health Corp is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| CVS | EMLC | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Health | Fixed Income |
52-Week High | $110.60 | $26.59 |
52-Week Low | $64.88 | $24.83 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
EMLC trades at $25.72, up 0.67% today, with a bullish technical signal driven by moving averages. Recent dividends include $0.14 paid in June 2026. The stock shows strong momentum indicators, though RSI levels suggest potential overbought conditions near-term.
Outlook remains positive given technical strength and dividend yield, but limited fundamental data availability warrants caution. Risks include emerging market volatility and Fed policy sensitivity. Analyst sentiment leans bullish, but investors should seek updated financial disclosures for full assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
